Home
Kjell-Morten Myhr's picture

Kjell-Morten Myhr

Professor
  • E-mailKjell-Morten.Myhr@uib.no
  • Phone+47 55 97 60 31+47 414 47 868
  • Visitor Address
    Haukeland Universitetssykehus Laboratoriebygget, 7. etg. Heis øst
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) (2022). The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis. European Radiology. 3576-3587.
  • Show author(s) (2022). The Effect of Smoking on Long-term Gray Matter Atrophy and Clinical Disability in Patients with Relapsing-Remitting Multiple Sclerosis. Neurology: Neuroimmunology and neuroinflammation. 1-10.
  • Show author(s) (2022). Strong tuberculin response after BCG vaccination is associated with low multiple sclerosis risk: a population-based cohort study. International Journal of Epidemiology. 1637-1644.
  • Show author(s) (2022). Safety of breast feeding during rituximab treatment in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry. 4 pages.
  • Show author(s) (2022). Ocrelizumab quantitation by liquid chromatography-tandem mass spectrometry. Journal of Mass Spectrometry and Advances in the Clinical Lab. 53-60.
  • Show author(s) (2022). Brief international cognitive assessment for MS (BICAMS) and global brain volumes in early stages of MS – A longitudinal correlation study. Multiple Sclerosis and Related Disorders.
  • Show author(s) (2022). Abuse and revictimization in adulthood in multiple sclerosis: a cross-sectional study during pregnancy. Journal of Neurology. 5901-5909.
  • Show author(s) (2021). Perinatal Depression and Anxiety in Women with Multiple Sclerosis: A Population-Based Cohort Study. Neurology. e2789-e2800.
  • Show author(s) (2021). Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations. Journal of Neurology, Neurosurgery and Psychiatry. 4 pages.
  • Show author(s) (2020). Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy. Neurology: Neuroimmunology and neuroinflammation. 1-8.
  • Show author(s) (2020). High incidence and prevalence of MS in Møre and Romsdal County, Norway, 1950–2018. Neurology: Neuroimmunology and neuroinflammation. 1-10.
  • Show author(s) (2019). Gut microbiota composition during a 12-week intervention with delayed-release dimethyl fumarate in multiple sclerosis – a pilot trial. Multiple Sclerosis Journal, Experimental, Translational and Clinical. 1-13.
  • Show author(s) (2018). α-Linolenic acid is associated with MRI activity in a prospective cohort of multiple sclerosis patients. Multiple Sclerosis. 987-993.
  • Show author(s) (2018). Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy. European Journal of Neurology. 527-534.
  • Show author(s) (2017). The prevalence and characteristics of epilepsy in patients with multiple sclerosis in Nordland county, Norway. Seizure. 131-135.
  • Show author(s) (2017). Survival and cause of death in multiple sclerosis: A 60-year longitudinal population study. Journal of Neurology, Neurosurgery and Psychiatry. 621-625.
  • Show author(s) (2017). Physical activity is associated with a decreased multiple sclerosis risk: The EnvIMS study. Multiple Sclerosis. 150-157.
  • Show author(s) (2017). Neurofilament light chain predicts disease activity in relapsing-remitting MS. Neurology: Neuroimmunology and neuroinflammation. 1-8.
  • Show author(s) (2017). Level of education and multiple sclerosis risk over a 50-year period: Registry-based sibling study. Multiple Sclerosis. 213-219.
  • Show author(s) (2017). In-depth cerebrospinal fluid quantitative proteome and deglycoproteome analysis: presenting a comprehensive picture of pathways and processes affected by multiple sclerosis. Journal of Proteome Research. 179-194.
  • Show author(s) (2017). Fourteen sequence variants that associate with multiple sclerosis discovered by meta-analysis informed by genetic correlations. NPJ GENOMIC MEDICINE. 12 pages.
  • Show author(s) (2017). Body size and physical exercise, and the risk of multiple sclerosis. Multiple Sclerosis. 270-278.
  • Show author(s) (2017). An update on cladribine for relapsing-remitting multiple sclerosis. Expert Opinion on Pharmacotherapy. 1627-1635.
  • Show author(s) (2017). 1,25-Dihydroxyvitamin-D3 induces brain proteomic changes in cuprizone mice during remyelination involving calcium proteins. Neurochemistry International. 262-277.
  • Show author(s) (2016). WT1 and interferon-β–vitamin D association in MS: a longitudinal study. Acta Neurologica Scandinavica. 309-312.
  • Show author(s) (2016). Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients. European Journal of Neurology. 1064-1070.
  • Show author(s) (2016). The influence of coping styles on long-term employment in multiple sclerosis: A prospective study. Multiple Sclerosis. 1008-1017.
  • Show author(s) (2016). The Brain Proteome of the Ubiquitin Ligase Peli1 Knock-Out Mouse during Experimental Autoimmune Encephalomyelitis. Journal of Proteomics & Bioinformatics.
  • Show author(s) (2016). The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology.
  • Show author(s) (2016). Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. Journal of Neurology, Neurosurgery and Psychiatry.
  • Show author(s) (2016). Preclinical disease activity in multiple sclerosis: A prospective study of cognitive performance prior to first symptom. Annals of Neurology. 616-624.
  • Show author(s) (2016). No association of tobacco use and disease activity in multiple sclerosis. Neurology: Neuroimmunology and neuroinflammation. 5 pages.
  • Show author(s) (2016). Negative interaction between smoking and EBV in the risk of multiple sclerosis: The EnvIMS study. Multiple Sclerosis. 1018-1024.
  • Show author(s) (2016). Level of education and multiple sclerosis risk after adjustment for known risk factors: The EnvIMS study. Multiple Sclerosis. 104-111.
  • Show author(s) (2016). Label-free analysis of human cerebrospinal fluid addressing various normalization strategies and revealing protein groups affected by multiple sclerosis. Proteomics. 1154-1165.
  • Show author(s) (2016). Increased levels of cell-free mitochondrial DNA in the cerebrospinal fluid of patients with multiple sclerosis. Mitochondrion (Amsterdam. Print). 32-35.
  • Show author(s) (2016). Does low socioeconomic status in early life protect against multiple sclerosis? A multinational, case-control study. European Journal of Neurology. 168-174.
  • Show author(s) (2016). Disease-modifying treatments for multiple sclerosis – a review of approved medications. European Journal of Neurology. 18-27.
  • Show author(s) (2016). CSF-PR 2.0: an interactive literature guide to quantitative cerebrospinal fluid mass spectrometry data from neurodegenerative disorders. Molecular & Cellular Proteomics. 300-309.
  • Show author(s) (2016). Allelic imbalance of multiple sclerosis susceptibility genes IKZF3 and IQGAP1 in human peripheral blood. BMC Genetics.
  • Show author(s) (2016). Alemtuzumab use in clinical practice: recommendations from European multiple sclerosis experts. CNS Drugs. 33-50.
  • Show author(s) (2016). A 60-year follow-up of the incidence and prevalence of multiple sclerosis in Hordaland County, Western Norway. Multiple Sclerosis. 100-105.
  • Show author(s) (2015). Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis. Journal of Neuroimmunology. 21-28.
  • Show author(s) (2015). Timing of use of cod liver oil, a vitamin D source, and multiple sclerosis risk: The EnvIMS study. Multiple Sclerosis. 1856-1864.
  • Show author(s) (2015). The EnvIMS study: Design and methodology of an international case-control study of environmental risk factors in multiple sclerosis. Neuroepidemiology. 173-181.
  • Show author(s) (2015). Reduced duration of breastfeeding is associated with a higher risk of multiple sclerosis in both Italian and Norwegian adult males: the EnvIMS study. Journal of Neurology. 1271-1277.
  • Show author(s) (2015). Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis. Proteomics. 3361-3369.
  • Show author(s) (2015). Magnetization transfer ratio does not correlate to myelin content in the brain in the MOG-EAE mouse model. Neurochemistry International. 28-40.
  • Show author(s) (2015). Identity-by-descent mapping in a Scandinavian multiple sclerosis cohort. European Journal of Human Genetics. 688-692.
  • Show author(s) (2015). Hereditary diffuse leukoencephalopathy with spheroids with phenotype of primary progressive multiple sclerosis. European Journal of Neurology. 328-333.
  • Show author(s) (2015). Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. Brain. 632-643.
  • Show author(s) (2015). Fingolimod does not enhance cerebellar remyelination in the cuprizone model. Journal of Neuroimmunology. 180-186.
  • Show author(s) (2015). Cerebrospinal fluid proteomics in multiple sclerosis. Biochimica et Biophysica Acta - Proteins and Proteomics. 746-756.
  • Show author(s) (2015). Body size and the risk of multiple sclerosis in Norway and Italy: The EnvIMS study. Multiple Sclerosis. 388-395.
  • Show author(s) (2015). Body mass index influence interferon-beta treatment response in multiple sclerosis. Journal of Neuroimmunology. 92-97.
  • Show author(s) (2014). Sun exposure and multiple sclerosis risk in Norway and Italy: The EnvIMS study. Multiple Sclerosis. 1042-1049.
  • Show author(s) (2014). Season of infectious mononucleosis and risk of multiple sclerosis at different latitudes; the EnvIMS Study. Multiple Sclerosis. 669-674.
  • Show author(s) (2014). Oligoclonal band phenotypes in MS differ in their HLA class II association, while specific KIR ligands at HLA class I show association to MS in general. Journal of Neuroimmunology. 174-179.
  • Show author(s) (2014). Month of birth and risk of multiple sclerosis: confounding and adjustments. Annals of clinical and translational neurology. 141-144.
  • Show author(s) (2014). Increasing serum levels of vitamin A, D and E are associated with alterations of different inflammation markers in patients with multiple sclerosis. Journal of Neuroimmunology. 60-65.
  • Show author(s) (2014). In-depth characterization of the cerebrospinal fluid (CSF) proteome displayed through the CSF proteome resource (CSF-PR). Molecular & Cellular Proteomics. 3152-3163.
  • Show author(s) (2014). Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: An explorative study. Multiple Sclerosis. 1074-1080.
  • Show author(s) (2014). Health related quality of life in patients recently diagnosed with multiple sclerosis. Acta Neurologica Scandinavica. 21-26.
  • Show author(s) (2014). Employment among patients with multiple sclerosis-A population study. PLOS ONE.
  • Show author(s) (2014). Effects of blood contamination and the rostro-caudal gradient on the human cerebrospinal fluid proteome. PLOS ONE.
  • Show author(s) (2014). Effect of high-dose 1.25 dihydroxyvitamin D3 on remyelination in the cuprizone model. APMIS : Acta pathologica, microbiologica et immunologica Scandinavica. Supplementum. 1178-1186.
  • Show author(s) (2014). Deficient phosphorylation of stat-1 in leukocytes identifies neutralizing antibodies in multiple sclerosis patients treated with interferon-beta. PLOS ONE.
  • Show author(s) (2014). Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study. Journal of Neurology, Neurosurgery and Psychiatry. 1109-1115.
  • Show author(s) (2014). Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis. Multiple Sclerosis. 1833-1840.
  • Show author(s) (2013). Sex ratio of multiple sclerosis in persons born from 1930 to 1979 and its relation to latitude in Norway. Journal of Neurology. 1481-1488.
  • Show author(s) (2013). Retinol levels are associated with magnetic resonance imaging outcomes in multiple sclerosis. Multiple Sclerosis. 451-457.
  • Show author(s) (2013). Network-based multiple sclerosis pathway analysis with GWAS data from 15,000 cases and 30,000 controls. American Journal of Human Genetics. 854-865.
  • Show author(s) (2013). Month of birth as a latitude-dependent risk factor for multiple sclerosis in Norway. Multiple Sclerosis. 1028-1034.
  • Show author(s) (2013). Inflammation markers in multiple sclerosis: CXCL16 reflects and may also predict disease activity. PLOS ONE. 9 pages.
  • Show author(s) (2013). Fat-soluble vitamins as disease modulators in multiple sclerosis. Acta Neurologica Scandinavica. 16-23.
  • Show author(s) (2013). Epstein-Barr virus is a necessary causative agent in the pathogenesis of multiple sclerosis: No. Multiple Sclerosis. 1692-1693.
  • Show author(s) (2013). Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Multiple Sclerosis. 1074-1083.
  • Show author(s) (2013). Deep gray matter demyelination detected by magnetization transfer ratio in the cuprizone model. PLOS ONE.
  • Show author(s) (2013). Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Multiple Sclerosis. 1533-1538.
  • Show author(s) (2013). Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature Genetics. 1353-1360.
  • Show author(s) (2013). Alpha-tocopherol and MRI outcomes in multiple sclerosis - association and prediction. PLOS ONE. 5 pages.
  • Show author(s) (2012). ω-3 fatty acid treatment in multiple sclerosis (OFAMS study): a randomised, double blind, placebo-controlled trial. Archives of Neurology. 1044-1051.
  • Show author(s) (2012). Vitamin D supplementation and monitoring in multiple sclerosis: who, when and wherefore. Acta Neurologica Scandinavica. 63-69.
  • Show author(s) (2012). Vitamin D and disease activity in multiple sclerosis before and during interferon beta treatment. Neurology. 267-273.
  • Show author(s) (2012). The Norwegian Multiple Sclerosis Registry and Biobank. Acta Neurologica Scandinavica. 20-23.
  • Show author(s) (2012). Modelling and Prediction of 25-Hydroxyvitamin D Levels in Norwegian Relapsing-Remitting Multiple Sclerosis Patients. Neuroepidemiology. 84-93.
  • Show author(s) (2011). Prevalence and incidence of multiple sclerosis in Oppland County – a cross-sectional population-based study in a landlocked county of Eastern Norway. Acta Neurologica Scandinavica. 250-257.
  • Show author(s) (2011). Fatigue in multiple sclerosis: associations with health-related quality of life and physical performance. European Journal of Neurology. 114-120.
  • Show author(s) (2011). Exploring the CLEC16A gene reveals a MS-associated variant with correlation to the relative expression of CLEC16A isoforms in thymus. Genes and Immunity. 191-198.
  • Show author(s) (2010). Upregulation of immunoglobulin-related genes in cortical sections from multiple sclerosis patients. Brain Pathology. 720-729.
  • Show author(s) (2010). Psychometric properties of a Norwegian version of Multiple Sclerosis Impact Scale (MSIS-29). Acta Neurologica Scandinavica. 244-251.
  • Show author(s) (2010). Progressive multifocal leucoencephalopathy in an immunocompetent patient with favourable outcome. A case report. BMC Neurology. 4 pages.
  • Show author(s) (2010). Postinfectious and chronic fatigue syndromes: clinical experience from a tertiary-referral centre in Norway. In Vivo. 185-188.
  • Show author(s) (2010). Benign multiple sclerosis: a need for a consensus. Acta Neurologica Scandinavica. 44-50.
  • Show author(s) (2010). A rare variant of the TYK2 gene is confirmed to be associated with multiple sclerosis. European Journal of Human Genetics. 502-504.
  • Show author(s) (2010). A multivariate approach to reveal biomarker signatures for disease classification: application to mass spectral profiles of cerebrospinal fluid from patients with multiple sclerosis. Journal of Proteome Research. 3608-3620.
  • Show author(s) (2009). Vitamin D treatment in multiple sclerosis. Journal of the Neurological Sciences. 104-108.
  • Show author(s) (2009). NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurology. 519-529.
  • Show author(s) (2009). Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway. Multiple Sclerosis. 942-950.
  • Show author(s) (2009). Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. The Lancet. 1503-1511.
  • Show author(s) (2009). Depressive symptoms and coping in newly diagnosed patients with multiple sclerosis. Multiple Sclerosis. 638-643.
  • Show author(s) (2009). Antibodies against interferon-beta in multiple sclerosis. Journal of Neuroimmunology. 148-150.
  • Show author(s) (2009). A coding polymorphism in NALP1 confers risk for autoimmune Addison's disease and type 1 diabetes. Genes and Immunity. 120-124.
  • Show author(s) (2008). Vitamin D-dependent rickets as a possible risk factor for multiple sclerosis. Archives of Neurology. 809-811.
  • Show author(s) (2008). The cuprizone model for demyelination. Acta Neurologica Scandinavica. 72-76.
  • Show author(s) (2008). The SH2D2A gene and susceptibility to multiple sclerosis. Journal of Neuroimmunology. 152-158.
  • Show author(s) (2008). Relationship of cognitive impairment to psychiatric symptoms in multiple sclerosis. Multiple Sclerosis. 1084-1090.
  • Show author(s) (2008). Quality of life among young patients with ischaemic stroke compared with patients with multiple sclerosis. Acta Neurologica Scandinavica. 181-185.
  • Show author(s) (2008). Pregnancy, delivery and birth outcome in different stages of maternal multiple sclerosis. Journal of Neurology. 623-627.
  • Show author(s) (2008). Environmental risk factors in multiple sclerosis. Acta Neurologica Scandinavica. 34-40.
  • Show author(s) (2008). Diagnosis and treatment of multiple sclerosis. Acta Neurologica Scandinavica. 12-21.
  • Show author(s) (2008). Depression and anxiety amongst multiple sclerosis patients. European Journal of Neurology. 239-245.
  • Show author(s) (2007). Prevalence of bladder, bowel and sexual problems among multiple sclerosis patients two to five years after diagnosis. Multiple Sclerosis. 106-112.
  • Show author(s) (2007). Pretreatment of mass spectral profiles: Application to proteomic data. Analytical Chemistry. 7014-7026.
  • Show author(s) (2007). Pre-analytical influence on the low molecular weight cerebrospinal fluid proteome. PROTEOMICS - Clinical Applications. 699-711.
  • Show author(s) (2007). Patient information and coping styles in multiple sclerosis. Multiple Sclerosis. 792-799.
  • Show author(s) (2007). Low frequency of the disease-associated DRB1*15-DQB1*06 haplotype may contribute to the low prevalence of multiple sclerosis in Sami. Tissue Antigens. 299-304.
  • Show author(s) (2007). Is smoking an extra hazard in pregnant MS women? Findings from a population-based registry in Norway. European Journal of Neurology. 1113-1117.
  • Show author(s) (2007). Health-related quality of life in secondary progressive multiple sclerosis. Multiple Sclerosis. 386-392.
  • Show author(s) (2007). Fc gamma receptor polymorphisms are not associated with autoimmune Addison's disease. Scandinavian Journal of Immunology. 555-558.
  • Show author(s) (2007). Familial effects on the clinical course of multiple sclerosis. Neurology. 376-383.
  • Show author(s) (2007). A follow-up study of Nordic multiple sclerosis candidate gene regions. Multiple Sclerosis. 584-589.
  • Show author(s) (2006). The Norwegian Multiple Sclerosis National Competence Centre and National Multiple Sclerosis Registry - a resource for clinical practice and research. Acta Neurologica Scandinavica. 37-40.
  • Show author(s) (2006). Planned vaginal births in women with multiple sclerosis: delivery and birth outcome. Acta Neurologica Scandinavica. 51-54.
  • Show author(s) (2006). Multippel sklerose. Norsk tidsskrift for logopedi. 5-9.
  • Show author(s) (2006). Multiplexed phosphoprotein analysis in immune cells. Acta Neurologica Scandinavica. 58-60.
  • Show author(s) (2006). Health-related quality of life among young adults with ischemic stroke on long-term follow-up. Stroke. 1232-2336.
  • Show author(s) (2006). Fc gamma R and multiple sclerosis: an overview. Acta Neurologica Scandinavica. 61-63.
  • Show author(s) (2006). Benign multiple sclerosis. Acta Neurologica Scandinavica. 55-57.
  • Show author(s) (2006). A 50-year follow-up of the incidence of multiple sclerosis in Hordaland County, Norway. Neurology. 182-186.
  • Show author(s) (2005). Mild depression in young adults with cerebral infarction at long-term follow-up: A population-based study. European Journal of Neurology. 194-198.
  • Show author(s) (2005). Fatigue at long-term follow-up in young adults with cerebral infarction. Cerebrovascular Diseases. 245-250.
  • Show author(s) (2005). Do all young ischemic stroke patients need long-term secondary preventive medication? Neurology. 609-611.
Academic lecture
  • Show author(s) (2022). Rituximab in the treatment of multiple sclerosis: A pharmacokinetic-pharmacodynamic model.
  • Show author(s) (2015). Vitamin D og interferon-behandling ved multippel sklerose.
  • Show author(s) (2015). Evidence of preclinical disease activity­ a prospective study on cognitive and physical performance prior to first symptom of multiple sclerosis.
  • Show author(s) (2014). Level of education and multiple sclerosis risk after adjustment for known risk factors: the EnvIMS study.
  • Show author(s) (2007). Target projection and proper data pre-treatment for the analysis of proteomic profiles.
  • Show author(s) (2007). Preteatment of Mass Spectral Profiles: Application to proteomic data.
  • Show author(s) (2007). Analysis of Proteomic Profiles.
  • Show author(s) (2006). Costs and quality of life in patients with multiple sclerosis in Norway compared to 9 other European countries.
  • Show author(s) (2000). Reduced quality of life among MS patients with sexual disturbance and bladder dysfunction.
  • Show author(s) (2000). Quality of life as a predictor for change in disability in multiple sclerosis.
  • Show author(s) (2000). Livskvalitet hos multippel sklerose pasienter - en utfordring for sykepleien.
  • Show author(s) (2000). Livskvalitet hos multippel sklerose pasienter.
  • Show author(s) (1999). The quality of life of multiple sclerosis patients in a treatment trial with recombinant interferon-alfa-2a.
  • Show author(s) (1999). Lack of agreement between objective disease measures and the Quality of Life in a treatment trial in multiple sclerosis.
  • Show author(s) (1999). Expanded Disability Status Scale scores and the Quality of Life of Multiple Sclerosis patients. An epidemiological study.
Abstract
  • Show author(s) (2017). alpha-Linolenic acid (ALA) serum levels are associated with reduced MRI activity in a prospective cohort of MS patients. Multiple Sclerosis. 712-712.
  • Show author(s) (2017). Cancer risk in multiple sclerosis. Multiple Sclerosis. 486-487.
  • Show author(s) (2013). Multivariate clinically isolated syndrome (CIS) risk factor study: towards individual prognosis and treatment indication in CIS. Multiple Sclerosis. 33-34.
  • Show author(s) (2013). Antibodies to Epstein-Barr virus and disease activity in multiple sclerosis. Multiple Sclerosis. 400-400.
  • Show author(s) (2012). WalkAide - A multidisciplinary model for adjustment and evaluation. Multiple Sclerosis. S30-S30.
  • Show author(s) (2012). Single cell pStat1 activation, a promising biomarker to evaluate neutralizing antibody effects in interferon-beta treated multiple sclerosis patients. Journal of Neuroimmunology. 18-19.
  • Show author(s) (2012). Poor sleep in patients with multiple sclerosis. European Journal of Neurology. 706-706.
  • Show author(s) (2012). Overweight as a risk factor for multiple sclerosis. European Journal of Neurology. 353-353.
  • Show author(s) (2012). Norwegian quality registry for biological drugs: the NOKBIL project. Scandinavian Journal of Rheumatology. 50-50.
  • Show author(s) (2012). An age at exposure effect between sun exposure and the risk of MS in Norway and Italy. Multiple Sclerosis. s15-s15.
  • Show author(s) (2011). VITAMIN D, LIFESTYLE FACTORS AND RISK OF MULTIPLE SCLEROSIS. European Journal of Neurology. 16-16.
  • Show author(s) (2011). The Risk of Multiple Sclerosis Among Petroleum Workers Exposed to Crude Oil and Other Hydrocarbons. Epidemiology. S60-S60.
  • Show author(s) (2010). Trend of association to the Glypican 5 gene region to multiple sclerosis. European Journal of Neurology. 221-221.
  • Show author(s) (2010). The definition of benign multiple sclerosis: a methodical approach. European Journal of Neurology. 494-494.
  • Show author(s) (2009). Massive up-regulation of immunoglobulin-related genes in the meninges of multiple sclerosis patients without evidence for Epstein-Barr virus infection. Multiple Sclerosis. S5-S5.
  • Show author(s) (2009). International case control study on risk factors for multiple sclerosis (MS): pilot testing the questionnaire. Multiple Sclerosis. 1403-1403.
  • Show author(s) (2009). Histopathological characterisation of the cuprizone model for demyelination. Multiple Sclerosis. S177-S177.
  • Show author(s) (2009). Fatigue in multiple sclerosis is associated with self-perceived health, but less with physical performance. Multiple Sclerosis. S225-S225.
  • Show author(s) (2008). Interferon-beta signal transduction, multiple sclerosis and auto-antibodies. Journal of Neuroimmunology. 134-135.
  • Show author(s) (2008). Gait and balance improved in patients with multiple sclerosis after inpatient physiotherapy. Multiple Sclerosis. S152-S152.
  • Show author(s) (2008). Fish diet prevents impaired mobility in the murine cuprizone model for multiple sclerosis. Multiple Sclerosis. S90-S91.
  • Show author(s) (2008). Early diagnosis and biomarker discovery from mass spectral profiles: application to multiple sclerosis. Multiple Sclerosis. S285-S285.
  • Show author(s) (2008). Biomarker discovery from mass spectral profiles: A combined proteomics and multivariate analysis. European Journal of Pharmaceutical Sciences. S27-S27.
  • Show author(s) (2008). An international case-control study of risk factors for multiple sclerosis. Multiple Sclerosis. S197-S197.
  • Show author(s) (2008). Acceptability and cross-cultural feasibility of it self-administered questionnaire on past exposure to putative environmental risk factors for multiple sclerosis. Multiple Sclerosis. S196-S196.
  • Show author(s) (2007). Smoking habits in pregnant MS women. European Journal of Neurology. 278-278.
  • Show author(s) (2007). Perinatal factors and later development of multiple sclerosis. Multiple Sclerosis. S91-S92.
  • Show author(s) (2007). Individualised physiotherapy improved fatigue score in patients with multiple sclerosis. Multiple Sclerosis. S127-S127.
  • Show author(s) (2007). Increasing prevalence of multiple sclerosis in the elderly in western Norway. Multiple Sclerosis. S96-S96.
  • Show author(s) (2006). The role of SH2D2A gene polymorphisms in multiple sclerosis. Multiple Sclerosis. S72-S72.
  • Show author(s) (2006). The role of SH2D2A gene polymorphisms in development of multiple sclerosis. Tissue Antigens. 528-529.
  • Show author(s) (2006). Pregnancy, delivery and birth outcome in mothers prior to debut of multiple sclerosis. European Journal of Neurology. 28-29.
  • Show author(s) (2006). Low prevalence of multiple sclerosis in a Sami population is related to low frequency of the disease-associated HLA DR15-DQ6 haplotype. Tissue Antigens. 523-523.
  • Show author(s) (2006). Low prevalence of multiple sclerosis and the HLA CR15-DQ6 halotype in Sami. Multiple Sclerosis. 71-71.
  • Show author(s) (2006). Health-related quality of life in secondary progressive multiple sclerosis. European Journal of Neurology. 27-27.
  • Show author(s) (2005). The CD28/CTLA4/ICOS gene region does not show assosiation in Norwegian multiple sclerosis patients. Genes and Immunity. 1 pages.
Academic literature review
  • Show author(s) (2022). Relationship between White Matter Lesions and Gray Matter Atrophy in Multiple Sclerosis. Neurology. E1562-E1573.
  • Show author(s) (2020). Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS. Multiple Sclerosis and Related Disorders. 1-10.
  • Show author(s) (2020). Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder. Journal of Neurology. 15 pages.
  • Show author(s) (2019). Neurofilament light chain as a biomarker in multiple sclerosis. Frontiers in Neurology. 1-6.
  • Show author(s) (2019). B cell depletion in the treatment of multiple sclerosis. Expert Opinion on Biological Therapy. 261-271.
  • Show author(s) (2017). Progressive multifocal leukoencephalopathy. Tidsskrift for Den norske legeforening. 10 pages.
  • Show author(s) (2015). Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades. Acta Neurologica Scandinavica. 29-36.
  • Show author(s) (2015). The Norwegian Multiple Sclerosis Registry and Biobank. Acta Neurologica Scandinavica. 24-28.
  • Show author(s) (2015). Country break-out session highlights. Neurodegenerative Disease Management. 31-37.
  • Show author(s) (2014). Multiple sclerosis registries in Europe - Results of a systematic survey. Multiple Sclerosis. 1523-1532.
  • Show author(s) (2014). Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. Neurology. 1210-1216.
  • Show author(s) (2013). Neuromyelitis optica. Tidsskrift for Den norske legeforening. 2057-2061.
  • Show author(s) (2013). Clinical assessment and management of sleep disorders in multiple sclerosis: a literature review. Acta Neurologica Scandinavica, Supplementum. 24-30.
  • Show author(s) (2012). Polyunsaturated fatty acids in multiple sclerosis therapy. Acta Neurologica Scandinavica. 70-75.
  • Show author(s) (2009). Corticosteroids in the treatment of multiple sclerosis. Acta Neurologica Scandinavica. 73-80.
  • Show author(s) (2003). New diagnostic criteria in multiple sclerosis. Tidsskrift for Den norske legeforening. 1345-1348.

More information in national current research information system (CRIStin)